A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
Histologically and/or cytologically proven NCCN locally advanced PC
Patients must have i) received at least one line of chemotherapy (any kind) OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery, or the patient does not wish to go through surgery.
DaRT indication validated by a multidisciplinary team.
Measurable lesion per RECIST (version 1.1) criteria
Concomitant chemotherapy or immunotherapy within the past 4 weeks
Prior radiation therapy to the pancreas
CA 19-9 > 1000 Units/ml
Fit for surgical exploration unless the patient refuses surgery
Alpha Tau Medical LTD.
Lead sponsor